Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats
Elwan, M., El-Nahass, E., Basyony, M., Elshennawy, E., El-Naggar, S. (2022). Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats. EKB Journal Management System, 6(1), 77-87. doi: 10.21608/jcbr.2021.95272.1231
Mona M. Elwan; Eman E. El-Nahass; Mohammed A. Basyony; Ehab O. Elshennawy; Sabry A. El-Naggar. "Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats". EKB Journal Management System, 6, 1, 2022, 77-87. doi: 10.21608/jcbr.2021.95272.1231
Elwan, M., El-Nahass, E., Basyony, M., Elshennawy, E., El-Naggar, S. (2022). 'Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats', EKB Journal Management System, 6(1), pp. 77-87. doi: 10.21608/jcbr.2021.95272.1231
Elwan, M., El-Nahass, E., Basyony, M., Elshennawy, E., El-Naggar, S. Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats. EKB Journal Management System, 2022; 6(1): 77-87. doi: 10.21608/jcbr.2021.95272.1231

Metformin treatment improves the hepato-renal dysfunctions induced in Type-II diabetes in male rats

Egyptian Journal of Cancer and Biomedical Research
Article 117, Volume 6, Issue 1, March 2022, Page 77-87  XML PDF (8.14 MB)
Document Type: Original Article
DOI: 10.21608/jcbr.2021.95272.1231
View on SCiNiTO View on SCiNiTO
Authors
Mona M. Elwan email orcid 1; Eman E. El-Nahass2; Mohammed A. Basyony3; Ehab O. Elshennawy4; Sabry A. El-Naggarorcid 5
1zoology department, faculty of science , tanta university
2zoology department, faulty of sciene, tanta university, tanta, egypt
3zoology,faculty of science , tanta university
4zoology department, faculty of science , tanta university, tanta, egypt
5Zoology Department, Faculty of Science, Tanta University, Tanta 3111, Egypt
Abstract
Background: Metformin is one of the alternative drugs to treat Diabetic mellitus type 2 (T2DM). One of the chronic symptoms of T2DM is the dysfunctionality of some vital organs. Aim: This study evaluates the role of metformin treatment to improve the liver and kidney functions of T2DM rats. Material and Methods: Forty rats were divided into four groups (n=10) as follows: group 1 (Gp1) was orally administered with 200 µl of distilled water. Gp2 was administered with metformin (200 mg/Kg) daily for two months. Gp3 and 4 were fed on high fat diet for 5 weeks, then Gp3 was injected with streptozotocin (STZ) (40 mg/Kg) once intraperitoneal (i.p.). Gp4 was injected with STZ as in Gp3 then administered with metformin as in Gp2. All rats were sacrificed to analyze the hematological, biochemical, and histopathological changes. Results: Metformin administration decreased the total body weight of both naïve and T2DM rats. Furthermore, metformin improves hepato-renal dysfunctions induced in T2DM rats as evidenced by decreasing the levels of ALT, AST, urea, and creatinine. The level of malondialdehyde was decreased while superoxide dismutase, catalase, and reduced glutathione levels were increased in the group of T2DM rats that were administrated with metformin. Treatment of T2DM rats with metformin increased C-Peptide and decreased glycose levels. Furthermore, histopathological investigations showed an improvement in the liver and kidney tissues upon treatment of T2DM rats with metformin. Conclusion: The treatment of T2DM rats with metformin for long period improves hepato-renal dysfunctions.
Keywords
Diabetes; Hepato-renal dysfunction; histopathological investigations; Metformin
Statistics
Article View: 192
PDF Download: 219